文献速递肝病

振动控制瞬时弹性成像的肝脏硬度测量改善原发性胆汁性胆管炎的结局预测

Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis.
PubMed 文献 · J Hepatol · 2022-06-28

这项国际多中心回顾性随访研究纳入12国23中心3985例原发性胆汁性胆管炎患者,验证振动控制瞬时弹性成像肝脏硬度测量(LSM)的预后价值。衍生队列2740例与验证队列568例中,LSM均独立预测不良临床结局,基线C统计量分别为0.83和0.92。8 kPa与15 kPa切点可区分低、中、高危组,40%患者属中高危。

要点

  • LSM每增加1 kPa,衍生队列校正HR为1.040(95%CI 1.026-1.054),验证队列为1.042(95%CI 1.029-1.056),均P<0.0001。
  • 基线校正C统计量在衍生队列为0.83(95%CI 0.79-0.87),验证队列为0.92(95%CI 0.89-0.95)。
  • 8 kPa与15 kPa切点最优区分低、中、高危组,40%患者按LSM属中高危。

核心结论

  • 振动控制瞬时弹性成像LSM是原发性胆汁性胆管炎结局的主要、独立、经验证的预测因素。
  • 应考虑将LSM作为原发性胆汁性胆管炎临床获益的替代终点。

研究设计与样本

  • 国际多中心回顾性随访研究,纳入12个国家23个中心的3985例原发性胆汁性胆管炎患者。
  • 纳入标准包括至少1次可靠的振动控制瞬时弹性成像LSM且随访≥1年。
  • 建立独立衍生队列(n=2740)和验证队列(n=568)。
  • 主要终点为至不良临床结局的时间,定义为肝脏相关并发症、肝移植或死亡。
  • 采用时间依赖多变量Cox回归分析确定风险比(HR)及置信区间(CI)。

主要发现

  • LSM在衍生队列(5324次LSM,平均随访5.0±3.1年)和验证队列(1470次LSM,平均随访5.0±2.8年)中均独立关联不良临床结局。
  • 每增加1 kPa的校正HR(95%CI)在衍生队列为1.040(1.026-1.054),验证队列为1.042(1.029-1.056),两者P均<0.0001。
  • 基线校正C统计量(95%CI)在衍生队列为0.83(0.79-0.87),验证队列为0.92(0.89-0.95)。
  • 在5至30 kPa范围内,对数HR随LSM呈单调函数增加。
  • LSM的预测价值随时间保持稳定,并改善生化应答标准、纤维化评分和预后评分的预后能力。

关键数值与推荐

  • LSM每增加1 kPa的校正HR(95%CI)在衍生队列为1.040(1.026-1.054),验证队列为1.042(1.029-1.056),均P<0.0001。
  • 基线校正C统计量(95%CI)在衍生队列为0.83(0.79-0.87),验证队列为0.92(0.89-0.95)。
  • 8 kPa和15 kPa切点最优区分低、中、高危组。

临床怎么用

  • 作者认为LSM是原发性胆汁性胆管炎结局的主要、独立、经验证的预测因素。
  • 作者认为应考虑将LSM作为原发性胆汁性胆管炎临床获益的替代终点。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) has been shown to predict outcomes of patients with primary biliary cholangitis (PBC) in small-size studies. We aimed to validate the prognostic value of LSM in a large cohort study. METHODS: We performed an international, multicentre, retrospective follow-up study of 3,985 patients with PBC seen at 23 centres in 12 countries. Eligibility criteria included at least 1 reliable LSM by VCTE and a follow-up ≥ 1 year. Independent derivation (n = 2,740) and validation (n = 568) cohorts were built. The primary endpoint was time to poor clinical outcomes defined as liver-related complications, liver transplantation, or death. Hazard ratios (HRs) with CIs were determined using a time-dependent multivariable Cox regression analysis. RESULTS: LSM was independently associated with poor clinical outcomes in the derivation (5,324 LSMs, mean follow-up 5.0 ± 3.1 years) and validation (1,470 LSMs, mean follow-up 5.0 ± 2.8 years) cohorts: adjusted HRs (95% CI) per additional kPa were 1.040 (1.026-1.054) and 1.042 (1.029-1.056), respectively (p <0.0001 for both). Adjusted C-statistics (95% CI) at baseline were 0.83 (0.79-0.87) and 0.92 (0.89-0.95), respectively. Between 5 and 30 kPa, the log-HR increased as a monotonic function of LSM. The predictive value of LSM was stable in time. LSM improved the prognostic ability of biochemical response criteria, fibrosis scores, and prognostic scores. The 8 kPa and 15 kPa cut-offs optimally separated low-, medium-, and high-risk groups. Forty percent of patients were at medium to high risk according to LSM. CONCLUSIONS: LSM by VCTE is a major, independent, validated predictor of PBC outcome. Its value as a surrogate endpoint for clinical benefit in PBC should be considered. LAY SUMMARY: Primary biliary cholangitis (PBC) is a chronic autoimmune disease, wherein the body's immune system mistakenly attacks the bile ducts. PBC progresses gradually, so surrogate markers (markers that predict clinically relevant outcomes like the need for a transplant or death long before the event occurs) are often needed to expedite the drug development and approval process. Herein, we show that liver stiffness measurement is a strong predictor of clinical outcomes and could be a useful surrogate endpoint in PBC trials.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Corpechot C, Carrat F, Gaouar F, et al. Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. J Hepatol. 2022. PMID: 35777587. doi:10.1016/j.jhep.2022.06.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。